A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This
 study is a randomized, multi-center, multinational, double blind, active-controlled, parallel
 design study of the combination of pyrotinib in combination with capecitabine versus placebo
 plus capecitabine in HER2+ MBC patients, who have prior received anthracyclin, taxane and
 trastuzumab.

 Patients will be randomized in a 2:1 ratio to one of the following treatment arms:

 Arm A: pyrotinib (400 mg once daily) + capecitabine (1000 mg/m^2 twice daily) Arm B: placebo
 (400 mg once daily) + capecitabine (1000 mg/m^2 twice daily) Patients will receive either arm
 of therapy until the occurrence of death, disease progression, unacceptable toxicity, or
 other specified withdrawal criterion.

 Patients in control group can be provide pyrotinib treatment when they progressed after the
 placebo plus capecitabine treatment.
This study is a phase 3, randomized, multi-center, multinational, double blind,
 active-controlled, parallel design study of the combination of pyrotinib in combination with
 capecitabine versus placebo plus capecitabine in HER2+ MBC patients, who have prior received
 anthracyclin, taxane and trastuzumab.

 Patients will be randomized in a 2:1 ratio to one of the following treatment arms:

 Arm A: pyrotinib (400 mg once daily) + capecitabine (1000 mg/m^2 twice daily) Arm B: placebo
 (400 mg once daily) + capecitabine (1000 mg/m^2 twice daily) Patients will receive either arm
 of therapy until the occurrence of death, disease progression, unacceptable toxicity, or
 other specified withdrawal criterion.

 Efficacy assessments will be performed at screening, every 6 weeks until cycle 18, every 12
 weeks thereafter.

 Patients in control group can be provide pyrotinib treatment when they progressed after the
 placebo plus capecitabine treatment. Pyrotinb will be administrated until the patients
 reached progress again or wit
Inclusion Criteria:

 1. Aged ≥18 and ≤75 years.

 2. ECOG performance status of 0 to 1.

 3. Life expectancy of more than 12 weeks.

 4. According to RECIST 1.1, at least one measurable lesion exists

 5. Histologically or cytologic confirmed HER2 positive advanced breast cancer which
 failed prior therapies.

 6. Prior treatment with trastuzumab(≥2 cycles in the metastatic setting, or ≥3 months in
 adjuvant setting), and the patients are not available for the trastuzumab or lapatinib

 7. Previously reveived both Anthracyclin and Taxane.

 8. Required laboratory values including following parameters:

 ANC: ≥ 1.5 x 10^9/L; Platelet count: ≥ 90 x 10^9/L; Hemoglobin: ≥ 9.0 g/dL; Total
 bilirubin: ≤ 1.5 x upper limit of normal (ULN); ALT and AST: ≤ 2 x ULN(patients with
 liver metastases: </= 5 x ULN); BUN and Creatinine: ≤ 1.5 x ULN;LVEF: ≥ 50%;QTcF: <
 470 ms.

 9. Signed informed consent

 Exclusion Criteria:

 1. Received previous therapy with lapatinib, neratinib, pyrotinib or any other HER2
 directe tyrosine kinase inhibitor.

 2. Received previous therapy with capecitabine.

 3. History of receiving chemotherapy, target-therapy or investigational treatment within
 28 days prior to randomization. Received hormone therapy within 7 days prior to
 randomization.

 4. Brain metastases that are untreated, symptomatic, or require therapy to control
 symptoms.

 5. Current severe, uncontrolled systemic disease.

 6. Unable or unwilling to swallow tablets.